[HTML][HTML] Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes
X Xu, Y Shi, Y Cai, Q Zhang, F Yang, H Chen, Y Gu… - PLoS …, 2013 - journals.plos.org
X Xu, Y Shi, Y Cai, Q Zhang, F Yang, H Chen, Y Gu, M Zhang, L Yu, T Yang
PLoS One, 2013•journals.plos.orgObjectives Follicular helper T (Tfh) cells exert an important role in autoimmune diseases.
Whether it might be involved in type 1 diabetes (T1D) is unknown. Our aim was to
investigate the role of Tfh cells in patients with T1D and the effect of anti-CD20 monoclonal
antibody (rituximab) on Tfh cells from T1D patients. Patients and Methods Fifty-four patients
with T1D and 37 healthy controls were enrolled in the current study. 20 of those patients
were treated with rituximab. The frequencies of circulating CD4+ CXCR5+ ICOS+ T cells …
Whether it might be involved in type 1 diabetes (T1D) is unknown. Our aim was to
investigate the role of Tfh cells in patients with T1D and the effect of anti-CD20 monoclonal
antibody (rituximab) on Tfh cells from T1D patients. Patients and Methods Fifty-four patients
with T1D and 37 healthy controls were enrolled in the current study. 20 of those patients
were treated with rituximab. The frequencies of circulating CD4+ CXCR5+ ICOS+ T cells …
Objectives
Follicular helper T (Tfh) cells exert an important role in autoimmune diseases. Whether it might be involved in type 1 diabetes (T1D) is unknown. Our aim was to investigate the role of Tfh cells in patients with T1D and the effect of anti-CD20 monoclonal antibody (rituximab) on Tfh cells from T1D patients.
Patients and Methods
Fifty-four patients with T1D and 37 healthy controls were enrolled in the current study. 20 of those patients were treated with rituximab. The frequencies of circulating CD4+CXCR5+ICOS+T cells were analyzed by flow cytometry. The serum autoantibodies were detected by radioligand assay. The levels of IL-21, IL-6 and BCL-6 were assessed using ELISA and/or real-time PCR.
Results
Increased frequencies of circulating Tfh cells together with enhanced expression of IL-21 were detected in patients. The correlation between the frequencies of circulating Tfh cells and the serum autoantibodies or C-peptide level was comfirmed. After rituximab therapy, follow-up analysis demonstrated that the frequencies of circulating Tfh cell and serum IA2A were decreased. The levels of IL-21, IL-6 and Bcl-6 mRNA were decreased after treatment. Furthermore, beta cell function in 10 of 20 patients was improved.
Conclusions
These data indicate Tfh cells may participate in the T1D-relatede immune responses and B cells might play a role in the development of Tfh responses in the disease progression.
PLOS